NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand
I'm LongbridgeAI, I can summarize articles.NRX Pharmaceuticals reported an $18.0M net loss for H1 2026, with cash on hand at $26.7M following a $22.3M public offering. The company aims to fund operations for at least one year via cash, revenue growth, and ATM facilities. Key developments include FDA review of its preservative-free ketamine ANDA, selection by DARPA for non-dilutive funding in the SPARC-TMS trial, and advancement of NRX-100 NDA using real-world evidence.
NRX Pharmaceuticals reported a net loss of $18.0 million for the six months ended June 30, 2026, and held approximately $26.7 million in cash and cash equivalents as of June 30, 2026. The company said operating loss widened to $11.3 million for the period and that a recent underwritten public offering raised gross proceeds of $22.3 million. Management expects existing cash, clinic revenue growth and access to an at-the-market facility to fund operations for at least one year.
Financial Highlights
- Net loss for six months ended June 30, 2026: $18.0 million (vs. $23.1 million in prior-year period).
- Net operating loss for six months ended June 30, 2026: $11.3 million (vs. $7.6 million in prior-year period).
- Cash and cash equivalents as of June 30, 2026: approximately $26.7 million (vs. $7.8 million at December 31, 2025).
- Completed institutionally-supported underwritten public offering: gross proceeds of $22.3 million (including full exercise of the underwriters’ option).
Business Highlights
- ANDA for preservative-free ketamine advanced through first-cycle FDA review with no drug-related major deficiencies; manufacturer’s attestation for the vial luer lock component submitted to FDA and company targets 2026 approval and commercialization.
- Initiated commercial-scale manufacturing of preservative-free ketamine with an initial launch stock goal of 5 million doses and planned post-launch output of ~1 million units per month.
- Selected by DARPA as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS; anticipated non-dilutive funding in excess of $11.5 million pending contracting.
- Advancing NRX-100 NDA using Real World Evidence from over 65,000 patients following supportive Presidential Executive Order and Congressional budget language; company aims for 2027 NDA approval.
- Invested in formation of Geneuro, advancing two clinical-stage monoclonal antibody programs (including Temelimab and GNK-301) with planned first-in-human GNK-301 trial targeted for July 2027 and expected non-dilutive governmental support.
- Expanded commercial capabilities: appointed first Chief Commercial Officer, retained a commercial launch team for preservative-free ketamine, and HOPE Therapeutics expanded clinical sites and became first U.S. commercial site using Zeta Surgical’s TMS navigation system.
Original SEC Filing: NRX Pharmaceuticals, Inc. [ NRXP ] - 8-K - Aug. 17, 2026